UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 15, 2015
 
Celsus Therapeutics Plc
(Exact name of registrant as specified in its charter)
 
England and Wales	 	001-36288	 	98-1034922	
(State or Other Jurisdiction of Incorporation)	 	(Commission File Number)	 	(IRS Employer Identification No.)	
 
The Gridiron Building
One Pancras Square
C/O Pearl Cohen Zedek Latzer Baratz UK LLP
London, N1C 4AG, United Kingdom
(Address of Principal Executive Offices)
 
Registrant’s telephone number, including area code +44-203-318-3004

(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
x	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

 	
 
 	Item 7.01.	Regulation FD Disclosure.	
 
Attached as Exhibit 99.l to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference is the investor presentation that will be used by Celsus Therapeutics Plc (“Celsus”) in making presentations to certain existing and potential stockholders of the Company with respect to the proposed acquisition (the “Business Combination”) of Volution Immuno Pharmaceuticals SA (“Volution”). In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the investor presentation attached to this report as Exhibit 99.1 is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

 	
 
 	Item 8.01.	Other Events	
 
Important Information and Where to Find It
 
Celsus and Volution and certain of their directors and executive officers may become participants in solicitation of proxies from Celsus shareholders in connection with the proposed transaction. Additional Information regarding persons who may, under the rules of the SEC, be deemed to be participants in the solicitation of the Celsus shareholders in connection with the proposed transaction, and who have interests, whether as security holders, directors or employees of Celsus or Volution or otherwise, which may be different from those of Celsus shareholders generally, will be provided in the proxy statement and other materials to be filed with the SEC.
 
Each member of Celsus's board of directors and Celsus's executive officers, and Volution's board of directors and Volution's executive officers may be deemed “participants” in the solicitation of proxies from the Celsus shareholders in connection with the proposed transaction.
 
Information regarding the special interests of these directors and executive officers in the transaction will be included in the proxy statement referred to above. Additional information regarding Celsus's directors' and executive officers' respective interests in Celsus by security holdings or otherwise is set forth in Celsus's proxy statement relating to the 2015 annual meeting of stockholders filed with the SEC on May 28, 2015.

 	
 
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. A definitive proxy statement and a proxy card will be filed with the SEC and will be mailed to Celsus's shareholders seeking any required shareholder approvals in connection with the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT CELSUS MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Shareholders may obtain, free of charge, copies of the definitive proxy statement and any other documents filed by Celsus with the SEC in connection with the proposed transaction at the SEC's website (http://www.sec.gov), at Celsus's website or by writing to Dov Elefant, CFO, Celsus Therapeutics Plc. at 24 West 40th Street, 8th Floor, New York, NY 10018.
 
Cautionary Note Regarding Forward-Looking Statements
 
The investor presentation attached hereto as Exhibit 99.1 contains certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.
 
Risks and uncertainties for Celsus and Volution and of the combined company include, but are not limited to: inability to complete the proposed business combination transaction; liquidity and trading market for ADSs prior to and following the consummation of the proposed transaction and any proposed financing; costs and potential litigation associated with the proposed transaction; failure or delay in obtaining required approvals by the SEC or any other governmental or quasi-governmental entity necessary to consummate the proposed transaction, including our ability to file an effective proxy statement in connection with the proposed transaction, which may also result in unexpected additional transaction expenses and operating cash expenditures on the parties; an inability or delay in obtaining required regulatory approvals for product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; failure to realize any value of certain product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for the combined company's products may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; unexpected cost increases and pricing pressures; failure to obtain the necessary shareholder approvals or to satisfy other conditions to the closing of the proposed transaction; uncertainties of cash flows and inability to meet working capital needs; cost reductions that may not result in anticipated level of cost savings or cost reductions prior to or after the consummation of the proposed transaction; and risks associated with the possible failure to realize certain benefits of the proposed transaction, including future financial, tax, accounting treatment, and operating results. Many of these factors that will determine actual results are beyond Celsus's, Volution's, or the combined company's ability to control or predict.
 
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in the presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in the presentation as a result of, among other factors, the factors referenced in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2014 and our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in the presentation, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in the presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of the presentation, except as required by law.
 
 	Item 9.01.	Financial Statements and Exhibits	
 
 	(d)	Exhibits.	
 
 	99.1	Investor Presentation	

 	
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 	CELSUS THERAPEUTICS PLC	

Date: July 15, 2015	/s/ Gur Roshwalb	
 	Gur Roshwalb
Chief Executive Officer	

 	

 
Exhibit 99.1

Celsus Therapeutics Plc (to be renamed Akari Therapeutics Plc) Celsus Therapeutics (CLTX) and Volution Immuno Pharmaceuticals SA July 2015

 	

Cautionary Note Regarding Forward - Looking Statements Certain statements in this presentation regarding the proposed business combination transaction with Volution Immuno Pharmaceuticals SA constitute "forward - looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are us ual ly identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and vari ati ons of such words or similar expressions. We intend these forward - looking statements to be covered by the safe harbor provisions for forward - looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These for ward - looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently avail abl e to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those for ward - looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual re sul ts may differ materially from those described in the forward - looking statements and will be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for Celsus and Volution and of the combined company include, but are not limited to: inability to com ple te the proposed business combination transaction; liquidity and trading market for ADSs prior to and following the consummation of the proposed transaction and an y p roposed financing; costs and potential litigation associated with the proposed transaction; failure or delay in obtaining required approvals by the SEC or any other go vernmental or quasi - governmental entity necessary to consummate the proposed transaction, including our ability to file an effective proxy statement in connection wi th the proposed transaction, which may also result in unexpected additional transaction expenses and operating cash expenditures on the parties; an inability or delay in obtain ing required regulatory approvals for product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in ob taining successful clinical results for product candidates and unexpected costs that may result therefrom; failure to realize any value of certain product candidates develop ed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; r isk s resulting from unforeseen side effects; risk that the market for the combined company's products may not be as large as expected; inability to obtain, maintain and enforc e p atents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturin g a rrangements with third party manufacturers or establish commercial scale manufacturing capabilities; unexpected cost increases and pricing pressures; failure to obtain the ne cessary shareholder approvals or to satisfy other conditions to the closing of the proposed transaction; uncertainties of cash flows and inability to meet working capital need s; cost reductions that may not result in anticipated level of cost savings or cost reductions prior to or after the consummation of the proposed transaction; and risks associated with the possible failure to realize certain benefits of the proposed transaction, including future financial, tax, accounting treatment, and operating results. Many of these factors th at will determine actual results are beyond Celsus's, Volution's, or the combined company's ability to control or predict. Other risks and uncertainties are more fully des cribed in periodic filings with the Securities and Exchange Commission (the "SEC"), including the factors described in the section entitled "Risk Factors" in our Quarterly Repo rt on Form 10 - Q for the quarter ended March 31, 2015 filed with the SEC, and in other filings that Celsus makes and will make with the SEC in connection with the proposed tr ans actions, including the proxy statement described below under "Important Information and Where to Find It." Existing and prospective investors are cautioned not to place undue re liance on these forward - looking statements, which speak only as of the date hereof. The statements made in this presentation speak only as of the date stated herein, and su bsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we und ertake any obligation, to update or revise any forward - looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward - looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. Important Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitati on of any vote or approval. In connection with the proposed transaction between Celsus and Volution, Celsus will file relevant materials with the Securities and Exchange Commis sio n (the “SEC”), including a definitive proxy statement which will be distributed to Celsus shareholders. INVESTORS AND SECURITY HOLDERS OF CELSUS ARE URGED TO READ THE PR OXY STATEMENT AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAI N I MPORTANT INFORMATION. Shareholders may obtain, free of charge, copies of the definitive proxy statement and any other documents filed by Celsus with the SEC in connection with the proposed transaction at the SEC's website (http://www.sec.gov), at Celsus's website or by writing to Dov Elefant, CFO, Celsus Th erapeutics Plc. at 24 West 40th Street, 8th Floor, New York, NY 10018. Additional information regarding the participants in the proxy solicitations and a description of their dir ect and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become av ail able . Copyright 2015 Co nfidential 1

 	

Combined Company Highlights • In line to become 2nd approved and best - in - class complement C5 inhibitor • Powerful inhibitor – 100% complement inhibition in Phase I trial • Evidence of efficacy equivalent to eculizumab in PNH blood model • Evidence of full complement inhibition in patients resistant to eculizumab • Once daily subcutaneous (SQ) injection provides significant patient benefit • Approved C5 inhibitor indications: Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic - Uremic Syndrome (aHUS) • $2.2 billion in global 2014 revenue, with rapid continuing growth expected • Expanding range of additional C5 - Inhibitor - related target indications • Initiate Phase II PNH trial in 4Q15; full data expected late 2016 • C ompassionate treatment for eculizumab - resistant patients starting late 2015 • Initiate Phase II trials in Guillain - Barré syndrome (GBS) and aHUS in 2016 • S hort duration clinical trials and potential rapid regulatory approvals Coversin Large, Proven Market Upcoming Milestones 2 Copyright 2015

 	

Executive Chairman (Volution) • Lead investor; serial entrepreneur; founder TDL, part of Sonic (SHL) Chief Executive Officer (Celsus) • Celsus; Venrock; Piper Jaffray; Internist Chief Operating Officer (Volution) • LEK Consulting; Head of Research, Investec; Clinisys Ltd. Medical Director (Volution) • European Medical Director, BMS; 25 years development exp. Chief Scientific Officer (Volution) • Coversin inventor; expert on parasite:host interactions Chief Financial Officer (Celsus) • Lev Pharmaceuticals; EpiCept; Synvista; Tetragenix SVP, Corporate Development (Volution) • Aprecia Pharmaceuticals; McKinsey Consulting; Sandoz GmbH Proven Management Team 3 Ray Prudo MD Gur Roshwalb MD, MBA Clive Richardson Dov Elefant Michael King MBA Wynne Weston - Davies, MD Miles Nunn PhD Copyright 2015

 	

PNH Eculizumab Resistance GBS aHUS Phase II Phase III Three Phase II Trials Initiating Within 18 Months 4 2017 2018 2015 2016 Phase II Phase III Compassionate use Phase II Phase III Ph Ib Copyright 2015

 	

Coversin Inhibits C5 – Proven Complement Target C3 C3b Classical Mannose binding lectin Alternative Activation pathways C3 convertase Opsonisation Amplification loop Liver, Macrophages, etc. C5 convertase C3a C5b C6 C7 C9 C8 C5 Inflammation autoimmunity C3b Anaphylatoxins Lysis and cell death C5a C5a and MAC act jointly on granulocytes and many other immune and tissue cell types - potentially causing inflammation and damage Complement system tightly regulated to prevent damage to self; if normal regulation fails or autoantibodies occur, significant tissue damage may result MAC Both Coversin and eculizumab act on C5 to prevent formation of C5a and the MAC 5 LTB4 (Coversin’s secondary binding site) Copyright 2015

 	

Expanding Opportunities In Complement - Related Therapeutics Ricklin D and Lambris JD. Nature Biotechnology 25, 1265 - 1275 (2007) 6 Approved or late - stage C5 - Inh indications Copyright 2015

 	

Coversin: Best - in - Class C5 Inhibitor • Coversin : 100% inhibition in 12 hours in Phase I trial ─ Other development - stage systemic C5 inhibitor products appear to inhibit no more than ~90% • Coversin and eculizumab bind to different regions of C5 α domain of C5 ─ Eculizumab inhibits C5 lytic activity by no more than 80% in resistant patients in our studies ─ Coversin inhibits all mammalian species tested ─ Eculizumab only inhibits human C5 • Subcutaneous, once - daily administration ─ Can also be given topically or by inhalation Coversin’s clinical and in - vitro data indicates efficacy for both PNH and eculizumab - resistant subgroups 7 C345C C5a C3b Bb Eculizumab epitope Position of Coversin binding Binding Sites Copyright 2015

 	

Coversin - Nature’s Complement Inhibitor • Coversin, a recombinant compact protein, was successfully synthesized and is now produced in E. coli by leading CMO • Manufacturing optimization and scale - up ongoing • Natural Coversin molecule works by damping down host immune responses, enabling tick to repeatedly feed without damage from inflammatory substances • Coversin derived from saliva of Ornithodoros moubata tick • Ticks have evolved to feed on the same hosts (300 million years of product development) 8 Copyright 2015

 	

Single D ose Phase Ia Clinical Trial Demonstrated 100% Inhibition and SQ Delivery Placebo n=2 Active n=4 • Full complement ablation within 12 hours at 0.57 mg/kg • Inhibition maintained for 24 hours after single dose • Good safety profile: no SAEs or injection site reactions 9 Change from Baseline (Individual) CH50 % activity • 24 normal volunteer subjects (16 active, 8 placebo) • Only highest dosing cohort (n=6) had CH50 testing done through full 96 hour period • Single subcutaneous dose at time 0 Copyright 2015

 	

Coversin Fully Effective in Blood of PNH Patients • Coversin and eculizumab have similar effects on lysis of PNH type III CD59 negative red blood cells • Doses above 10µg/ml Coversin and 50µg/ml eculizumab do not further inhibit lysis of CD59 negative red blood cells Acidified serum + MgCl (lysis) Acidified serum + MgCl + 50µg/ml eculizumab Acidified serum + MgCl + 10µg/ml Coversin Coversin inhibits PNH red blood cell lysis as effectively as eculizumab at a molar equivalent dose 10 PNH cells PNH cells destroyed PNH cell protected by eculizumab PNH cells protected by Coversin Heat inactivated acidified serum + MgCl (no C5, no lysis) Copyright 2015

 	

Coversin Completely Ablated Complement Activity in Patient Unresponsive to E culizumab Serum from European patient with p.Arg885His polymorphism in C5 that confers resistance to eculizumab Resistant serum not fully inhibited by eculizumab Resistant serum and normal human serum both fully inhibited by Coversin (dashed lines). NC (solid red line) fully inhibited by eculizumab Serum with eculizumab (Ecu) S erum with Coversin (Cov) Resistant serum (BJ) Normal control serum (NC) 11 Coversin inhibits complement fully and equally well in normal control AND eculizumab - resistant serum Copyright 2015

 	

Coversin Development Strategy 12 • PNH and aHUS regulatory approvals • Rapid and full ablation • Long term patient safety data • SQ self administration (vs. current IV) • Patients resistant to full eculizumab binding • New indications leverage Coversin’s small physical size Take Advantage of E culizumab’s Proven Success Leverage Coversin’s Differentiation Copyright 2015

 	

PNH Phase II Data By YE 2016 • Ascending dose trial • 60 mg loading dose – then daily fixed doses for 5 days • Continuation under single CTA direct into Phase II • O pen label trial • Primary efficacy endpoint: LDH at 28 days • Secondary efficacy endpoints: Hgb , transfusions, hemoglobinuria and QOL • Projected first patient dosing by YE 2015 • Randomised comparative trial with eculizumab • Open label design; 1:1 randomisation; patients treated for six months and then enter long - term extension study • Two groups: treatment naïve and switching from eculizumab 13 2015 Phase 1b 2016 Phase II 2017 Phase III Copyright 2015

 	

Coversin Compassionate Use Program in E culizumab - Resistant Patients • Eculizumab resistance recently identified – First identified mutation*: 3.5% of Japanese population – Ongoing efforts to determine prevalence of this & other mutations • Preclinical in - vitro validation activities – Identified and successfully tested non - Japanese cases • Clinical treatment – Demand from clinicians to treat patients on compassionate use – Treatment to begin on EU patients in 2015 – Reimbursement possible in many major markets 14 * Nishimura et al . , New England Journal of Medicine 2014 ; 370 : 632 - 9 Copyright 2015

 	

Coversin Targeting First GBS Approval • Guillain Barré syndrome ( GBS): acute immune - mediated polyneuropathy leading to destruction of myelin sheath − Standard of care is treatment with IVIG or PE ─ Short term: 20 – 30% require me chanical ventilation ─ Long term: 2 – 12% die; 10 – 35 % have permanent impairment • Coversin demonstrated robust preclinical efficacy • Over 6,000 patients treated in US per year • Attractive clinical trial duration: 28 days + 6 month follow up ─ Primary endpoint: 1 point improvement in GBS Disability Rating Scale relative to Coversin vs. placebo added to standard of care ─ 1 point = difference between wheelchair - bound or ambulatory 15 Copyright 2015

 	

Coversin Targeting Approval for aHUS • Complement - mediated hemolytic uremic syndrome (aHUS ): chronic and life - threatening genetic disease characterized by microangio - pathic hemolytic anemia, thrombocytopenia, and kidney injury • Estimated 10,000 patients across North America and Europe • Eculizumab received accelerated FDA approval in 2011 – Data from prospective and retrospective trials in 67 patients • Coversin open label Phase II aHUS clinical trial planned for 2H 2016 – Endpoints include normalization of hematologic parameters, kidney function and discontinuation of plasma therapy – Approximately 10 patients 16 Copyright 2015

 	

IP Summary • 2 US and 18 foreign issued patents, expiring 2024 - 2031* • Current patent portfolio covers US, major European countries, Japan, Australia, Brazil, Canada, China , and New Zealand • Ongoing activities to further extend IP barriers to market entry in specific indications • Coversin will have orphan drug and BLA market exclusivity barriers in both US and EU for each approved indication 17 * Excluding patent term extensions Copyright 2015

 	

1H 2017 2H 2016 1H 2016 Near - Term Milestones 2H 2015 18 • Phase Ib trial • Initiate PNH Phase II trial • Initiate treatment of eculizumab - resistant patients • Long - term toxicity studies • CMC optimization • Initial data from compassionate use program • US IND - including Orphan and Fast Track status • Initiate GBS Phase II trial • CMC scale - up • Data from PNH Phase II trial • Initiate aHUS Phase II trial • Second CMO • Initiate PNH Phase III trial • Data from GBS Phase II trial Copyright 2015

 	

Coversin - Best - In - Class C5 Inhibitor • Coversin - Nature’s C omplement C5 Inhibitor – In line to become 2nd approved and best - in - class complement C5 inhibitor – Powerful inhibitor – 100% complement inhibition in Phase I trial – Evidence of efficacy equivalent to eculizumab in PNH blood model – Evidence of full complement inhibition in patients resistant to eculizumab – Once daily subcutaneous (SQ) injection provides significant patient benefit • Multiple near - term clinical readouts within 18 months – Initiate Phase II PNH trial in 4Q15; full data expected late 2016 – Compassionate treatment for eculizumab - resistant patients starting late 2015 – Initiate Phase II trials in Guillain - Barré syndrome (GBS) and aHUS in 2016 – Short duration clinical trials and rapid regulatory approvals 19 Copyright 2015

 	

Celsus Therapeutics Plc (to be renamed Akari Therapeutics Plc) Celsus Therapeutics (CLTX) and Volution Immuno Pharmaceuticals SA July 2015